Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind,...

Area of Science:

• Dermatology
• Aesthetics
• Pharmacology

Background:

• CBL-514 is an injectable small-molecule drug.
• It has shown promise for subcutaneous fat reduction.

Purpose of the Study:

• To evaluate the efficacy and safety of CBL-514 for abdominal subcutaneous fat reduction.
• Assessed changes in fat thickness and volume via ultrasound.

Main Methods:

• Phase 2, single-blind, randomized, placebo-controlled trial.
• 76 participants received up to 4 treatments of CBL-514 or placebo.
• Primary endpoint: proportion of participants with ≥150 mL subcutaneous fat volume loss.

Main Results:

• Significantly more CBL-514 participants achieved ≥150 mL fat volume loss vs. placebo.
• At 8 weeks post-treatment, 69.6% of CBL-514 group achieved this, versus 0% in placebo (P < .001).
• Mild-to-moderate injection site reactions were the most common adverse events.

Conclusions:

• CBL-514 significantly reduced abdominal subcutaneous fat volume.
• The drug has a favorable safety profile.
• CBL-514 presents a promising noninvasive therapy for targeted fat reduction.